<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02969018</url>
  </required_header>
  <id_info>
    <org_study_id>B7931004</org_study_id>
    <secondary_id>2016-004049-96</secondary_id>
    <nct_id>NCT02969018</nct_id>
  </id_info>
  <brief_title>Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis</brief_title>
  <official_title>A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-06700841 IN SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether PF-06700841 is safe and effective in the&#xD;
      treatment of chronic plaque psoriasis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Actual">March 2018</completion_date>
  <primary_completion_date type="Actual">March 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12</measure>
    <time_frame>Baseline (Day 1 pre-dose), Week 12</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percentage of body surface area (BSA) affected. In each area, the sum of the severity rating scores for erythema, induration and scaling is multiplied by the score representing the percentage of this area involved by psoriasis, multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4). The sum of the numbers obtained for each of the four body areas is the PASI. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>A PASI75 response is a 75% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PASI Scores at Week 4 by Induction Dose</measure>
    <time_frame>Baseline (Day 1 pre-dose), Week 4</time_frame>
    <description>Change from baseline in PASI scores at Week 4 was presented by induction dose (ie, PF-06700841 60 mg QD, 30 mg QD, and placebo). The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16</measure>
    <time_frame>Weeks 1, 2, 4, 6, 8, 10, 14, 16</time_frame>
    <description>A PASI75 response is a 75% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16</measure>
    <time_frame>Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16</time_frame>
    <description>A PASI50 response is a 50% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16</measure>
    <time_frame>Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16</time_frame>
    <description>A PASI90 response is a 90% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16</measure>
    <time_frame>Baseline (Day 1 pre-dose), Weeks 1, 2, 4, 6, 8, 10, 14, 16</time_frame>
    <description>The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16</measure>
    <time_frame>Baseline (Day 1 pre-dose), Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16</time_frame>
    <description>The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>From first dose of study treatment (Day 1) up to Week 20</time_frame>
    <description>An AE (non-serious and serious) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or an important medical event. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Discontinued From the Study Due to Treatment-Emergent AEs</measure>
    <time_frame>From first dose of study treatment (Day 1) up to Week 20</time_frame>
    <description>The number of participants who discontinued from the study due to treatment-emergent AEs is presented. Note for data reported under this Outcome Measure: Per sponsor reporting standard, pregnancy was counted as AE for AE data tables while it was counted separately in the disposition data table (Participant Flow Module).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Blood Lipid Level at Weeks 4 and 12</measure>
    <time_frame>Baseline (Day 1 pre-dose), Weeks 4 and 12</time_frame>
    <description>Lipid panel included low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, total cholesterol, and triglycerides.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Post-Baseline Laboratory Test Abnormalities</measure>
    <time_frame>From first dose of study treatment (Day 1) up to Week 16</time_frame>
    <description>Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology (hemoglobin, hematocrit, erythrocytes, reticulocytes, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils, monocytes, activated partial thromboplastin time, prothrombin time [PT], PT/international normalized ratio; chemistry (total bilirubin, direct bilirubin, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, alkaline phosphatase, protein, albumin, urea nitrogen, creatinine, urate, total cholesterol, LDL and HDL cholesterol, triglycerides, calcium, sodium, potassium, chloride, bicarbonate, glucose, creatine kinase, Cystatin C, glomerular filtration rate; urinalysis (pH, urine glucose, ketones, urine protein, urine hemoglobin, nitrites, leukocyte esterase, urine erythrocytes, urine leukocytes, hyaline casts, bacteria, choriogonadotropin beta).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Post-Baseline Vital Sign Abnormalities</measure>
    <time_frame>From first dose of study treatment (Day 1) up to Week 16</time_frame>
    <description>Vital signs categorical summarization criteria: 1) sitting systolic blood pressure (SBP) &lt;90 millimeters of mercury (mmHg); 2) sitting diastolic blood pressure (DBP) &lt;50 mmHg; 3) sitting pulse rate &lt;40 or &gt;120 beats per minute (bpm); 4) change from baseline (increase or decrease) in sitting DBP greater than or equal to (&gt;=) 20 mmHg; 5) change from baseline (increase or decrease) in sitting SBP &gt;=30 mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities</measure>
    <time_frame>From first dose of study treatment (Day 1) up to Week 16</time_frame>
    <description>ECG categorical summarization criteria: 1) QRS duration (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): &gt;=140 milliseconds (msec), &gt;=50% change from baseline; 2) PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): &gt;=300 msec, &gt;=25% change when baseline is &gt; 200 msec or &gt;=50% change when baseline is less than or equal to (&lt;=) 200 msec; 3) QT interval (time from ECG Q wave to the end of the T wave corresponding to electrical systole): absolute value of &gt;=500 msec; 4) QTc interval (QT corrected for heart rate): absolute value of 450 to &lt;480 msec, 480 to &lt;500 msec, &gt;=500 msec; a change from baseline of 30 to &lt;60 msec or &gt;=60 msec.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">212</enrollment>
  <condition>Chronic Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>PF-06700841 60 mg followed by 30 mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of 30 mg PF-06700841 once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06700841 60 mg followed by 10 mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of 10 mg PF-06700841 once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06700841 60mg once daily followed by 100mg once weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of 100 mg PF-06700841 once weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06700841 60mg once daily followed by placebo once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of placebo once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06700841 30mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 week induction with 30 mg PF-06700841 once daily followed by 8 week chronic administration of 30 mg PF-06700841 once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06700841 30mg once daily followed by 10mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 week induction with 30 mg PF-06700841 once daily, followed by 8 week chronic administration of 10 mg PF-06700841 once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06700841 30mg once daily followed by 100mg once weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 week induction with 30 mg PF-06700841 once daily, followed by 8 week chronic administration of 100 mg PF-06700841 once weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>12 weeks once daily placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06700841</intervention_name>
    <arm_group_label>PF-06700841 30mg once daily</arm_group_label>
    <arm_group_label>PF-06700841 30mg once daily followed by 100mg once weekly</arm_group_label>
    <arm_group_label>PF-06700841 30mg once daily followed by 10mg once daily</arm_group_label>
    <arm_group_label>PF-06700841 60 mg followed by 10 mg once daily</arm_group_label>
    <arm_group_label>PF-06700841 60 mg followed by 30 mg once daily</arm_group_label>
    <arm_group_label>PF-06700841 60mg once daily followed by 100mg once weekly</arm_group_label>
    <arm_group_label>PF-06700841 60mg once daily followed by placebo once daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have had a diagnosis of plaque psoriasis (psoriasis vulgaris) for at least 6 months&#xD;
             prior to Baseline/Day 1 (prior to first dose of study drug)&#xD;
&#xD;
          -  Have a PASI score of 12 or greater AND a PGA score of 3 (&quot;moderate&quot;) or 4 (&quot;severe&quot;)&#xD;
             at Baseline/Day 1 (prior to first dose of study drug)&#xD;
&#xD;
          -  Have plaque-type psoriasis covering at least 10% of total body surface area (BSA) at&#xD;
             Baseline/Day 1 (prior to first dose of study drug)&#xD;
&#xD;
          -  Considered by dermatologist investigator to be a candidate for systemic therapy or&#xD;
             phototherapy of psoriasis (either naïve or history of previous treatment)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently have non-plaque forms of psoriasis, eg, erythrodermic, guttate, or pustular&#xD;
             psoriasis, with the exception of nail psoriasis which is allowed&#xD;
&#xD;
          -  Have evidence of skin conditions (eg, eczema) at the time of screening or baseline&#xD;
             visit that would interfere with the evaluation of psoriasis&#xD;
&#xD;
          -  Cannot discontinue systemic therapies and/or topical therapies for the treatment of&#xD;
             psoriasis and cannot discontinue phototherapy (UVB or PUVA)&#xD;
&#xD;
          -  Have previously been treated with Secukinumab (Cosentyx), and Ixekizumab (Taltz).&#xD;
&#xD;
          -  Have taken Apremilast (Otezla) within 3 months of first dose of study drug.&#xD;
&#xD;
          -  Have undergone treatment with tofacitinib within 3 months of first dose.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwest Arkansas Clinical Trials Center, PLLC/Hull Dermatology, PA</name>
      <address>
        <city>Rogers</city>
        <state>Arkansas</state>
        <zip>72758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anaheim Clinical Trials, LLC</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Dermatology &amp; Clinical Research Institute</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emil A. Tanghetti, MD dba Center for Dermatology and Laser Surgery</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern California Dermatology</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tower Saint John's Imaging</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Science Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park Avenue Dermatology Administrative Annex</name>
      <address>
        <city>Orange Park</city>
        <state>Florida</state>
        <zip>32073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park Avenue Dermatology</name>
      <address>
        <city>Orange Park</city>
        <state>Florida</state>
        <zip>32073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Olympian Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rose Radiology</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forward Clinical Trials, Inc</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33624</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dundee Dermatology</name>
      <address>
        <city>West Dundee</city>
        <state>Illinois</state>
        <zip>60118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dawes Fretzin Clinical Research Group, LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dawes Fretzin Dermatology Group, LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psoriasis Treatment Center of Central New Jersey</name>
      <address>
        <city>East Windsor</city>
        <state>New Jersey</state>
        <zip>08520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Rockefeller University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Search of Rochester, Inc.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Drug Services, UNC Hospitals</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Dermatology and Skin Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Clinical and Translation Research Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Health Science Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vital Prospects Clinical Research Institute, P.C</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Concepts</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lee Medical Associates, PA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Progressive Clinical Research, PA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Dermatology and Laser Specialists</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Clinical Research, Inc.</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wiseman Dermatology Research Inc.</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3M 3Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynderm Research Inc</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research by ICLS</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6J 7W5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Centre for Dermatology</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J 5K2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Centre for Dermatology</name>
      <address>
        <city>Richmond Hill</city>
        <state>Ontario</state>
        <zip>L4B 1A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>K.Papp Clinical Research Inc.</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diex Research Sherbrooke Inc.</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1L 0H8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche Dermatologique du Quebec metropolitain (CRDQ)</name>
      <address>
        <city>Quebec</city>
        <zip>G1V4X7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Enel-Med Przychodnia Grunwaldzka</name>
      <address>
        <city>Gdansk</city>
        <zip>80-266</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Badan Klinicznych PI-House Sp. z o.o.</name>
      <address>
        <city>Gdansk</city>
        <zip>80-546</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermoklinika Centrum Medyczne s.c. M.Kierstan, J. Narbutt, A. Lesiak</name>
      <address>
        <city>Lodz</city>
        <zip>90-436</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ &quot;Nasz Lekarz&quot; - Praktyka Grupowa Lekarzy Rodzinnych z Przychodnia Specjalistyczna</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MTZ Clinical Research Sp. z o.o.</name>
      <address>
        <city>Warszawa</city>
        <zip>02-106</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WroMedica s.c.</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-685</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7931004&amp;StudyName=A+Phase+2a%2C+Randomized%2C+Double-blind%2C+Placebo-controlled+Study+To+Evaluate+Safety+And+Efficacy+Of+Pf-06700841+In+Subjects+With+Moderate+To+Severe+Plaque+Psoriasis</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>November 17, 2016</study_first_submitted>
  <study_first_submitted_qc>November 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2016</study_first_posted>
  <results_first_submitted>February 13, 2019</results_first_submitted>
  <results_first_submitted_qc>March 28, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 29, 2019</results_first_posted>
  <last_update_submitted>March 28, 2019</last_update_submitted>
  <last_update_submitted_qc>March 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>plaque psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>PF-06700841</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 13, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT02969018/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 10, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT02969018/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD</title>
          <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 30 mg QD (blinded tablets).</description>
        </group>
        <group group_id="P2">
          <title>PF-06700841 60 mg QD Followed by 10 mg QD</title>
          <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).</description>
        </group>
        <group group_id="P3">
          <title>PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)</title>
          <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).</description>
        </group>
        <group group_id="P4">
          <title>PF-06700841 60 mg QD Followed by Placebo</title>
          <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of matching placebo QD (blinded tablets).</description>
        </group>
        <group group_id="P5">
          <title>PF-06700841 30 mg QD</title>
          <description>Participants received 12 weeks of blinded PF-06700841 30 mg QD tablets.</description>
        </group>
        <group group_id="P6">
          <title>PF-06700841 30 mg QD Followed by 10 mg QD</title>
          <description>Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).</description>
        </group>
        <group group_id="P7">
          <title>PF-06700841 30 mg QD Followed by 100 mg QW</title>
          <description>Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).</description>
        </group>
        <group group_id="P8">
          <title>Placebo</title>
          <description>Participants received 12 weeks of blinded matching placebo QD tablets.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="25"/>
                <participants group_id="P5" count="29"/>
                <participants group_id="P6" count="25"/>
                <participants group_id="P7" count="30"/>
                <participants group_id="P8" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="27"/>
                <participants group_id="P6" count="17"/>
                <participants group_id="P7" count="22"/>
                <participants group_id="P8" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No Longer Meets Eligibility Criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliance With Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants who received at least 1 dose of PF-06700841 or placebo.</population>
      <group_list>
        <group group_id="B1">
          <title>PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD</title>
          <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 30 mg QD (blinded tablets).</description>
        </group>
        <group group_id="B2">
          <title>PF-06700841 60 mg QD Followed by 10 mg QD</title>
          <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).</description>
        </group>
        <group group_id="B3">
          <title>PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)</title>
          <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).</description>
        </group>
        <group group_id="B4">
          <title>PF-06700841 60 mg QD Followed by Placebo</title>
          <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of matching placebo QD (blinded tablets).</description>
        </group>
        <group group_id="B5">
          <title>PF-06700841 30 mg QD</title>
          <description>Participants received 12 weeks of blinded PF-06700841 30 mg QD tablets.</description>
        </group>
        <group group_id="B6">
          <title>PF-06700841 30 mg QD Followed by 10 mg QD</title>
          <description>Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).</description>
        </group>
        <group group_id="B7">
          <title>PF-06700841 30 mg QD Followed by 100 mg QW</title>
          <description>Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).</description>
        </group>
        <group group_id="B8">
          <title>Placebo</title>
          <description>Participants received 12 weeks of blinded matching placebo QD tablets.</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="26"/>
            <count group_id="B4" value="25"/>
            <count group_id="B5" value="29"/>
            <count group_id="B6" value="25"/>
            <count group_id="B7" value="30"/>
            <count group_id="B8" value="23"/>
            <count group_id="B9" value="212"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.0" spread="14.69"/>
                    <measurement group_id="B2" value="44.6" spread="13.71"/>
                    <measurement group_id="B3" value="45.5" spread="12.93"/>
                    <measurement group_id="B4" value="48.4" spread="15.47"/>
                    <measurement group_id="B5" value="44.2" spread="10.92"/>
                    <measurement group_id="B6" value="44.0" spread="11.56"/>
                    <measurement group_id="B7" value="43.2" spread="12.28"/>
                    <measurement group_id="B8" value="50.3" spread="12.23"/>
                    <measurement group_id="B9" value="46.0" spread="13.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>18-44 Years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="14"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="88"/>
                  </measurement_list>
                </category>
                <category>
                  <title>45-64 Years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="13"/>
                    <measurement group_id="B7" value="16"/>
                    <measurement group_id="B8" value="12"/>
                    <measurement group_id="B9" value="109"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 Years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="17"/>
                    <measurement group_id="B7" value="23"/>
                    <measurement group_id="B8" value="19"/>
                    <measurement group_id="B9" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="23"/>
                    <measurement group_id="B6" value="20"/>
                    <measurement group_id="B7" value="26"/>
                    <measurement group_id="B8" value="19"/>
                    <measurement group_id="B9" value="179"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="27"/>
                    <measurement group_id="B6" value="22"/>
                    <measurement group_id="B7" value="25"/>
                    <measurement group_id="B8" value="19"/>
                    <measurement group_id="B9" value="189"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percentage of body surface area (BSA) affected. In each area, the sum of the severity rating scores for erythema, induration and scaling is multiplied by the score representing the percentage of this area involved by psoriasis, multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4). The sum of the numbers obtained for each of the four body areas is the PASI. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.</description>
        <time_frame>Baseline (Day 1 pre-dose), Week 12</time_frame>
        <population>All randomized participants who received at least 1 dose of investigational product (PF-06700841 or placebo) and had observed PASI data for Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 30 mg QD (blinded tablets).</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 60 mg QD Followed by 10 mg QD</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 60 mg QD Followed by Placebo</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of matching placebo QD (blinded tablets).</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841 30 mg QD</title>
            <description>Participants received 12 weeks of blinded PF-06700841 30 mg QD tablets.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841 30 mg QD Followed by 10 mg QD</title>
            <description>Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841 30 mg QD Followed by 100 mg QW</title>
            <description>Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Participants received 12 weeks of blinded matching placebo QD tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percentage of body surface area (BSA) affected. In each area, the sum of the severity rating scores for erythema, induration and scaling is multiplied by the score representing the percentage of this area involved by psoriasis, multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4). The sum of the numbers obtained for each of the four body areas is the PASI. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.</description>
          <population>All randomized participants who received at least 1 dose of investigational product (PF-06700841 or placebo) and had observed PASI data for Week 12.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="21"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="19"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.85" lower_limit="-18.31" upper_limit="-13.39"/>
                    <measurement group_id="O2" value="-10.56" lower_limit="-12.96" upper_limit="-8.16"/>
                    <measurement group_id="O3" value="-14.28" lower_limit="-16.75" upper_limit="-11.81"/>
                    <measurement group_id="O4" value="-10.14" lower_limit="-12.62" upper_limit="-7.66"/>
                    <measurement group_id="O5" value="-17.28" lower_limit="-19.55" upper_limit="-15.02"/>
                    <measurement group_id="O6" value="-13.27" lower_limit="-15.78" upper_limit="-10.76"/>
                    <measurement group_id="O7" value="-11.88" lower_limit="-14.16" upper_limit="-9.59"/>
                    <measurement group_id="O8" value="-7.21" lower_limit="-9.96" upper_limit="-4.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <p_value_desc>Hochberg adjusted p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-8.64</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.232</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.33</ci_lower_limit>
            <ci_upper_limit>-4.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0963</p_value>
            <p_value_desc>Hochberg adjusted p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-3.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.206</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.99</ci_lower_limit>
            <ci_upper_limit>0.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0046</p_value>
            <p_value_desc>Hochberg adjusted p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-7.07</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.233</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.76</ci_lower_limit>
            <ci_upper_limit>-3.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0963</p_value>
            <p_value_desc>Hochberg adjusted p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-2.93</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.238</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.63</ci_lower_limit>
            <ci_upper_limit>0.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Hochberg adjusted p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-10.07</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.152</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.63</ci_lower_limit>
            <ci_upper_limit>-6.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0158</p_value>
            <p_value_desc>Hochberg adjusted p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-6.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.255</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.79</ci_lower_limit>
            <ci_upper_limit>-2.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0488</p_value>
            <p_value_desc>Hochberg adjusted p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-4.66</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.163</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.24</ci_lower_limit>
            <ci_upper_limit>-1.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 12</title>
        <description>A PASI75 response is a 75% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.</description>
        <time_frame>Week 12</time_frame>
        <population>All participants who received at least 1 dose of investigational product (PF-06700841 or placebo) with PASI data at Week 12 after non-responder imputation applied.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 30 mg QD (blinded tablets).</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 60 mg QD Followed by 10 mg QD</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 60 mg QD Followed by Placebo</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of matching placebo QD (blinded tablets).</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841 30 mg QD</title>
            <description>Participants received 12 weeks of blinded PF-06700841 30 mg QD tablets.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841 30 mg QD Followed by 10 mg QD</title>
            <description>Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841 30 mg QD Followed by 100 mg QW</title>
            <description>Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Participants received 12 weeks of blinded matching placebo QD tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 12</title>
          <description>A PASI75 response is a 75% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.</description>
          <population>All participants who received at least 1 dose of investigational product (PF-06700841 or placebo) with PASI data at Week 12 after non-responder imputation applied.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0" lower_limit="41.68" upper_limit="76.44"/>
                    <measurement group_id="O2" value="24.1" lower_limit="11.92" upper_limit="40.60"/>
                    <measurement group_id="O3" value="57.7" lower_limit="39.84" upper_limit="74.16"/>
                    <measurement group_id="O4" value="24.0" lower_limit="11.01" upper_limit="41.95"/>
                    <measurement group_id="O5" value="86.2" lower_limit="71.16" upper_limit="95.15"/>
                    <measurement group_id="O6" value="24.0" lower_limit="11.01" upper_limit="41.95"/>
                    <measurement group_id="O7" value="36.7" lower_limit="22.11" upper_limit="53.31"/>
                    <measurement group_id="O8" value="13.0" lower_limit="3.65" upper_limit="30.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>10.00</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.95</ci_lower_limit>
            <ci_upper_limit>33.87</ci_upper_limit>
            <other_analysis_desc>Logistic regression</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.12</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>7.36</ci_upper_limit>
            <other_analysis_desc>Logistic regression</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>9.09</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.71</ci_lower_limit>
            <ci_upper_limit>30.48</ci_upper_limit>
            <other_analysis_desc>Logistic regression</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.11</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>7.55</ci_upper_limit>
            <other_analysis_desc>Logistic regression</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>41.67</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.80</ci_lower_limit>
            <ci_upper_limit>160.68</ci_upper_limit>
            <other_analysis_desc>Logistic regression</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.11</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>7.55</ci_upper_limit>
            <other_analysis_desc>Logistic regression</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.86</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.17</ci_lower_limit>
            <ci_upper_limit>12.74</ci_upper_limit>
            <other_analysis_desc>Logistic regression</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PASI Scores at Week 4 by Induction Dose</title>
        <description>Change from baseline in PASI scores at Week 4 was presented by induction dose (ie, PF-06700841 60 mg QD, 30 mg QD, and placebo). The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.</description>
        <time_frame>Baseline (Day 1 pre-dose), Week 4</time_frame>
        <population>All participants who received at least 1 dose of investigational product (PF-06700841 or placebo) and had observed PASI data at Week 4.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841 60 mg QD as the Induction Dose</title>
            <description>Participants received PF-06700841 60 mg QD as the induction dose.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 30 mg QD as the Induction Dose</title>
            <description>Participants received PF-06700841 30 mg QD as the induction dose.</description>
          </group>
          <group group_id="O3">
            <title>Placebo as the Induction Dose</title>
            <description>Participants received matching placebo QD as the induction dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PASI Scores at Week 4 by Induction Dose</title>
          <description>Change from baseline in PASI scores at Week 4 was presented by induction dose (ie, PF-06700841 60 mg QD, 30 mg QD, and placebo). The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.</description>
          <population>All participants who received at least 1 dose of investigational product (PF-06700841 or placebo) and had observed PASI data at Week 4.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.17" lower_limit="-14.20" upper_limit="-12.15"/>
                    <measurement group_id="O2" value="-12.16" lower_limit="-13.31" upper_limit="-11.02"/>
                    <measurement group_id="O3" value="-4.17" lower_limit="-6.38" upper_limit="-1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-9.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.470</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.43</ci_lower_limit>
            <ci_upper_limit>-6.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-7.99</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.502</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.48</ci_lower_limit>
            <ci_upper_limit>-5.51</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16</title>
        <description>A PASI75 response is a 75% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.</description>
        <time_frame>Weeks 1, 2, 4, 6, 8, 10, 14, 16</time_frame>
        <population>All participants who received at least 1 dose of investigational product (PF-06700841 or placebo) with PASI data for each specified time point after non-responder imputation applied.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 30 mg QD (blinded tablets).</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 60 mg QD Followed by 10 mg QD</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 60 mg QD Followed by Placebo</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of matching placebo QD (blinded tablets).</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841 30 mg QD</title>
            <description>Participants received 12 weeks of blinded PF-06700841 30 mg QD tablets.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841 30 mg QD Followed by 10 mg QD</title>
            <description>Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841 30 mg QD Followed by 100 mg QW</title>
            <description>Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Participants received 12 weeks of blinded matching placebo QD tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16</title>
          <description>A PASI75 response is a 75% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.</description>
          <population>All participants who received at least 1 dose of investigational product (PF-06700841 or placebo) with PASI data for each specified time point after non-responder imputation applied.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.00" upper_limit="11.29"/>
                    <measurement group_id="O2" value="6.9" lower_limit="1.24" upper_limit="20.16"/>
                    <measurement group_id="O3" value="7.7" lower_limit="1.38" upper_limit="22.29"/>
                    <measurement group_id="O4" value="4.0" lower_limit="0.20" upper_limit="17.61"/>
                    <measurement group_id="O5" value="0" lower_limit="0.00" upper_limit="9.81"/>
                    <measurement group_id="O6" value="4.0" lower_limit="0.20" upper_limit="17.61"/>
                    <measurement group_id="O7" value="0" lower_limit="0.00" upper_limit="9.50"/>
                    <measurement group_id="O8" value="0" lower_limit="0.00" upper_limit="12.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="1.44" upper_limit="23.10"/>
                    <measurement group_id="O2" value="13.8" lower_limit="4.85" upper_limit="28.84"/>
                    <measurement group_id="O3" value="26.9" lower_limit="13.38" upper_limit="44.68"/>
                    <measurement group_id="O4" value="12.0" lower_limit="3.35" upper_limit="28.17"/>
                    <measurement group_id="O5" value="3.4" lower_limit="0.18" upper_limit="15.34"/>
                    <measurement group_id="O6" value="8.0" lower_limit="1.44" upper_limit="23.10"/>
                    <measurement group_id="O7" value="0" lower_limit="0.00" upper_limit="9.50"/>
                    <measurement group_id="O8" value="0" lower_limit="0.00" upper_limit="12.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" lower_limit="11.01" upper_limit="41.95"/>
                    <measurement group_id="O2" value="41.4" lower_limit="25.89" upper_limit="58.25"/>
                    <measurement group_id="O3" value="61.5" lower_limit="43.57" upper_limit="77.43"/>
                    <measurement group_id="O4" value="36.0" lower_limit="20.24" upper_limit="54.39"/>
                    <measurement group_id="O5" value="27.6" lower_limit="14.53" upper_limit="44.29"/>
                    <measurement group_id="O6" value="24.0" lower_limit="11.01" upper_limit="41.95"/>
                    <measurement group_id="O7" value="36.7" lower_limit="22.11" upper_limit="53.31"/>
                    <measurement group_id="O8" value="0" lower_limit="0.00" upper_limit="12.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.0" lower_limit="26.99" upper_limit="62.14"/>
                    <measurement group_id="O2" value="41.4" lower_limit="25.89" upper_limit="58.25"/>
                    <measurement group_id="O3" value="65.4" lower_limit="47.38" upper_limit="80.60"/>
                    <measurement group_id="O4" value="36.0" lower_limit="20.24" upper_limit="54.39"/>
                    <measurement group_id="O5" value="51.7" lower_limit="35.20" upper_limit="67.97"/>
                    <measurement group_id="O6" value="28.0" lower_limit="13.95" upper_limit="46.22"/>
                    <measurement group_id="O7" value="26.7" lower_limit="14.02" upper_limit="42.99"/>
                    <measurement group_id="O8" value="8.7" lower_limit="1.57" upper_limit="24.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0" lower_limit="41.68" upper_limit="76.44"/>
                    <measurement group_id="O2" value="37.9" lower_limit="22.93" upper_limit="54.88"/>
                    <measurement group_id="O3" value="65.4" lower_limit="47.38" upper_limit="80.60"/>
                    <measurement group_id="O4" value="32.0" lower_limit="17.03" upper_limit="50.36"/>
                    <measurement group_id="O5" value="65.5" lower_limit="48.57" upper_limit="79.95"/>
                    <measurement group_id="O6" value="20.0" lower_limit="8.23" upper_limit="37.54"/>
                    <measurement group_id="O7" value="40.0" lower_limit="24.95" upper_limit="56.61"/>
                    <measurement group_id="O8" value="8.7" lower_limit="1.57" upper_limit="24.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.0" lower_limit="30.51" upper_limit="65.86"/>
                    <measurement group_id="O2" value="24.1" lower_limit="11.92" upper_limit="40.60"/>
                    <measurement group_id="O3" value="61.5" lower_limit="43.57" upper_limit="77.43"/>
                    <measurement group_id="O4" value="32.0" lower_limit="17.03" upper_limit="50.36"/>
                    <measurement group_id="O5" value="72.4" lower_limit="55.71" upper_limit="85.47"/>
                    <measurement group_id="O6" value="28.0" lower_limit="13.95" upper_limit="46.22"/>
                    <measurement group_id="O7" value="46.7" lower_limit="30.85" upper_limit="63.01"/>
                    <measurement group_id="O8" value="13.0" lower_limit="3.65" upper_limit="30.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.0" lower_limit="30.51" upper_limit="65.86"/>
                    <measurement group_id="O2" value="17.2" lower_limit="7.05" upper_limit="32.89"/>
                    <measurement group_id="O3" value="34.6" lower_limit="19.40" upper_limit="52.62"/>
                    <measurement group_id="O4" value="16.0" lower_limit="5.66" upper_limit="32.96"/>
                    <measurement group_id="O5" value="75.9" lower_limit="59.40" upper_limit="88.08"/>
                    <measurement group_id="O6" value="16.0" lower_limit="5.66" upper_limit="32.96"/>
                    <measurement group_id="O7" value="16.7" lower_limit="6.81" upper_limit="31.90"/>
                    <measurement group_id="O8" value="8.7" lower_limit="1.57" upper_limit="24.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.0" lower_limit="20.24" upper_limit="54.39"/>
                    <measurement group_id="O2" value="10.3" lower_limit="2.88" upper_limit="24.61"/>
                    <measurement group_id="O3" value="30.8" lower_limit="16.33" upper_limit="48.70"/>
                    <measurement group_id="O4" value="20.0" lower_limit="8.23" upper_limit="37.54"/>
                    <measurement group_id="O5" value="58.6" lower_limit="41.75" upper_limit="74.11"/>
                    <measurement group_id="O6" value="12.0" lower_limit="3.35" upper_limit="28.17"/>
                    <measurement group_id="O7" value="16.7" lower_limit="6.81" upper_limit="31.90"/>
                    <measurement group_id="O8" value="8.7" lower_limit="1.57" upper_limit="24.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16</title>
        <description>A PASI50 response is a 50% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.</description>
        <time_frame>Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16</time_frame>
        <population>All participants who received at least 1 dose of investigational product (PF-06700841 or placebo) with PASI data for each specified time point after non-responder imputation applied.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 30 mg QD (blinded tablets).</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 60 mg QD Followed by 10 mg QD</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 60 mg QD Followed by Placebo</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of matching placebo QD (blinded tablets).</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841 30 mg QD</title>
            <description>Participants received 12 weeks of blinded PF-06700841 30 mg QD tablets.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841 30 mg QD Followed by 10 mg QD</title>
            <description>Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841 30 mg QD Followed by 100 mg QW</title>
            <description>Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Participants received 12 weeks of blinded matching placebo QD tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16</title>
          <description>A PASI50 response is a 50% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.</description>
          <population>All participants who received at least 1 dose of investigational product (PF-06700841 or placebo) with PASI data for each specified time point after non-responder imputation applied.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" lower_limit="3.35" upper_limit="28.17"/>
                    <measurement group_id="O2" value="13.8" lower_limit="4.85" upper_limit="28.84"/>
                    <measurement group_id="O3" value="19.2" lower_limit="7.90" upper_limit="36.26"/>
                    <measurement group_id="O4" value="20.0" lower_limit="8.23" upper_limit="37.54"/>
                    <measurement group_id="O5" value="10.3" lower_limit="2.88" upper_limit="24.61"/>
                    <measurement group_id="O6" value="8.0" lower_limit="1.44" upper_limit="23.10"/>
                    <measurement group_id="O7" value="3.3" lower_limit="0.17" upper_limit="14.86"/>
                    <measurement group_id="O8" value="0" lower_limit="0.00" upper_limit="12.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.0" lower_limit="26.99" upper_limit="62.14"/>
                    <measurement group_id="O2" value="37.9" lower_limit="22.93" upper_limit="54.88"/>
                    <measurement group_id="O3" value="46.2" lower_limit="29.21" upper_limit="63.79"/>
                    <measurement group_id="O4" value="32.0" lower_limit="17.03" upper_limit="50.36"/>
                    <measurement group_id="O5" value="41.4" lower_limit="25.89" upper_limit="58.25"/>
                    <measurement group_id="O6" value="20.0" lower_limit="8.23" upper_limit="37.54"/>
                    <measurement group_id="O7" value="33.3" lower_limit="19.33" upper_limit="49.94"/>
                    <measurement group_id="O8" value="0" lower_limit="0.00" upper_limit="12.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0" lower_limit="41.68" upper_limit="76.44"/>
                    <measurement group_id="O2" value="69.0" lower_limit="52.10" upper_limit="82.75"/>
                    <measurement group_id="O3" value="69.2" lower_limit="51.30" upper_limit="83.67"/>
                    <measurement group_id="O4" value="68.0" lower_limit="49.64" upper_limit="82.97"/>
                    <measurement group_id="O5" value="69.0" lower_limit="52.10" upper_limit="82.75"/>
                    <measurement group_id="O6" value="60.0" lower_limit="41.68" upper_limit="76.44"/>
                    <measurement group_id="O7" value="66.7" lower_limit="50.06" upper_limit="80.67"/>
                    <measurement group_id="O8" value="13.0" lower_limit="3.65" upper_limit="30.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.0" lower_limit="53.78" upper_limit="86.05"/>
                    <measurement group_id="O2" value="62.1" lower_limit="45.12" upper_limit="77.07"/>
                    <measurement group_id="O3" value="73.1" lower_limit="55.32" upper_limit="86.62"/>
                    <measurement group_id="O4" value="68.0" lower_limit="49.64" upper_limit="82.97"/>
                    <measurement group_id="O5" value="82.8" lower_limit="67.11" upper_limit="92.95"/>
                    <measurement group_id="O6" value="60.0" lower_limit="41.68" upper_limit="76.44"/>
                    <measurement group_id="O7" value="63.3" lower_limit="46.69" upper_limit="77.89"/>
                    <measurement group_id="O8" value="26.1" lower_limit="12.02" upper_limit="45.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.0" lower_limit="53.78" upper_limit="86.05"/>
                    <measurement group_id="O2" value="55.2" lower_limit="38.44" upper_limit="71.07"/>
                    <measurement group_id="O3" value="73.1" lower_limit="55.32" upper_limit="86.62"/>
                    <measurement group_id="O4" value="52.0" lower_limit="34.14" upper_limit="69.49"/>
                    <measurement group_id="O5" value="86.2" lower_limit="71.16" upper_limit="95.15"/>
                    <measurement group_id="O6" value="56.0" lower_limit="37.86" upper_limit="73.01"/>
                    <measurement group_id="O7" value="63.3" lower_limit="46.69" upper_limit="77.89"/>
                    <measurement group_id="O8" value="17.4" lower_limit="6.17" upper_limit="35.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.0" lower_limit="49.64" upper_limit="82.97"/>
                    <measurement group_id="O2" value="44.8" lower_limit="28.93" upper_limit="61.56"/>
                    <measurement group_id="O3" value="73.1" lower_limit="55.32" upper_limit="86.62"/>
                    <measurement group_id="O4" value="48.0" lower_limit="30.51" upper_limit="65.86"/>
                    <measurement group_id="O5" value="86.2" lower_limit="71.16" upper_limit="95.15"/>
                    <measurement group_id="O6" value="48.0" lower_limit="30.51" upper_limit="65.86"/>
                    <measurement group_id="O7" value="56.7" lower_limit="40.16" upper_limit="72.13"/>
                    <measurement group_id="O8" value="17.4" lower_limit="6.17" upper_limit="35.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.0" lower_limit="49.64" upper_limit="82.97"/>
                    <measurement group_id="O2" value="44.8" lower_limit="28.93" upper_limit="61.56"/>
                    <measurement group_id="O3" value="69.2" lower_limit="51.30" upper_limit="83.67"/>
                    <measurement group_id="O4" value="52.0" lower_limit="34.14" upper_limit="69.49"/>
                    <measurement group_id="O5" value="89.7" lower_limit="75.39" upper_limit="97.12"/>
                    <measurement group_id="O6" value="48.0" lower_limit="30.51" upper_limit="65.86"/>
                    <measurement group_id="O7" value="53.3" lower_limit="36.99" upper_limit="69.15"/>
                    <measurement group_id="O8" value="21.7" lower_limit="8.98" upper_limit="40.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.0" lower_limit="45.61" upper_limit="79.76"/>
                    <measurement group_id="O2" value="44.8" lower_limit="28.93" upper_limit="61.56"/>
                    <measurement group_id="O3" value="61.5" lower_limit="43.57" upper_limit="77.43"/>
                    <measurement group_id="O4" value="48.0" lower_limit="30.51" upper_limit="65.86"/>
                    <measurement group_id="O5" value="89.7" lower_limit="75.39" upper_limit="97.12"/>
                    <measurement group_id="O6" value="36.0" lower_limit="20.24" upper_limit="54.39"/>
                    <measurement group_id="O7" value="36.7" lower_limit="22.11" upper_limit="53.31"/>
                    <measurement group_id="O8" value="26.1" lower_limit="12.02" upper_limit="45.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0" lower_limit="41.68" upper_limit="76.44"/>
                    <measurement group_id="O2" value="34.5" lower_limit="20.05" upper_limit="51.43"/>
                    <measurement group_id="O3" value="53.8" lower_limit="36.21" upper_limit="70.79"/>
                    <measurement group_id="O4" value="40.0" lower_limit="23.56" upper_limit="58.32"/>
                    <measurement group_id="O5" value="79.3" lower_limit="63.20" upper_limit="90.58"/>
                    <measurement group_id="O6" value="40.0" lower_limit="23.56" upper_limit="58.32"/>
                    <measurement group_id="O7" value="36.7" lower_limit="22.11" upper_limit="53.31"/>
                    <measurement group_id="O8" value="21.7" lower_limit="8.98" upper_limit="40.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16</title>
        <description>A PASI90 response is a 90% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.</description>
        <time_frame>Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16</time_frame>
        <population>All participants who received at least 1 dose of investigational product (PF-06700841 or placebo) with PASI data for each specified time point after non-responder imputation applied.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 30 mg QD (blinded tablets).</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 60 mg QD Followed by 10 mg QD</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 60 mg QD Followed by Placebo</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of matching placebo QD (blinded tablets).</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841 30 mg QD</title>
            <description>Participants received 12 weeks of blinded PF-06700841 30 mg QD tablets.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841 30 mg QD Followed by 10 mg QD</title>
            <description>Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841 30 mg QD Followed by 100 mg QW</title>
            <description>Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Participants received 12 weeks of blinded matching placebo QD tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16</title>
          <description>A PASI90 response is a 90% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.</description>
          <population>All participants who received at least 1 dose of investigational product (PF-06700841 or placebo) with PASI data for each specified time point after non-responder imputation applied.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.00" upper_limit="11.29"/>
                    <measurement group_id="O2" value="3.4" lower_limit="0.18" upper_limit="15.34"/>
                    <measurement group_id="O3" value="0" lower_limit="0.00" upper_limit="10.88"/>
                    <measurement group_id="O4" value="0" lower_limit="0.00" upper_limit="11.29"/>
                    <measurement group_id="O5" value="0" lower_limit="0.00" upper_limit="9.81"/>
                    <measurement group_id="O6" value="0" lower_limit="0.00" upper_limit="11.29"/>
                    <measurement group_id="O7" value="0" lower_limit="0.00" upper_limit="9.50"/>
                    <measurement group_id="O8" value="0" lower_limit="0.00" upper_limit="12.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.00" upper_limit="11.29"/>
                    <measurement group_id="O2" value="3.4" lower_limit="0.18" upper_limit="15.34"/>
                    <measurement group_id="O3" value="7.7" lower_limit="1.38" upper_limit="22.29"/>
                    <measurement group_id="O4" value="0" lower_limit="0.00" upper_limit="11.29"/>
                    <measurement group_id="O5" value="0" lower_limit="0.00" upper_limit="9.81"/>
                    <measurement group_id="O6" value="0" lower_limit="0.00" upper_limit="11.29"/>
                    <measurement group_id="O7" value="0" lower_limit="0.00" upper_limit="9.50"/>
                    <measurement group_id="O8" value="0" lower_limit="0.00" upper_limit="12.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" lower_limit="3.35" upper_limit="28.17"/>
                    <measurement group_id="O2" value="20.7" lower_limit="9.42" upper_limit="36.80"/>
                    <measurement group_id="O3" value="42.3" lower_limit="25.84" upper_limit="60.16"/>
                    <measurement group_id="O4" value="16.0" lower_limit="5.66" upper_limit="32.96"/>
                    <measurement group_id="O5" value="6.9" lower_limit="1.24" upper_limit="20.16"/>
                    <measurement group_id="O6" value="8.0" lower_limit="1.44" upper_limit="23.10"/>
                    <measurement group_id="O7" value="3.3" lower_limit="0.17" upper_limit="14.86"/>
                    <measurement group_id="O8" value="0" lower_limit="0.00" upper_limit="12.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" lower_limit="5.66" upper_limit="32.96"/>
                    <measurement group_id="O2" value="20.7" lower_limit="9.42" upper_limit="36.80"/>
                    <measurement group_id="O3" value="26.9" lower_limit="13.38" upper_limit="44.68"/>
                    <measurement group_id="O4" value="12.0" lower_limit="3.35" upper_limit="28.17"/>
                    <measurement group_id="O5" value="24.1" lower_limit="11.92" upper_limit="40.60"/>
                    <measurement group_id="O6" value="8.0" lower_limit="1.44" upper_limit="23.10"/>
                    <measurement group_id="O7" value="20.0" lower_limit="9.09" upper_limit="35.70"/>
                    <measurement group_id="O8" value="0" lower_limit="0.00" upper_limit="12.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" lower_limit="11.01" upper_limit="41.95"/>
                    <measurement group_id="O2" value="17.2" lower_limit="7.05" upper_limit="32.89"/>
                    <measurement group_id="O3" value="30.8" lower_limit="16.33" upper_limit="48.70"/>
                    <measurement group_id="O4" value="8.0" lower_limit="1.44" upper_limit="23.10"/>
                    <measurement group_id="O5" value="34.5" lower_limit="20.05" upper_limit="51.43"/>
                    <measurement group_id="O6" value="4.0" lower_limit="0.20" upper_limit="17.61"/>
                    <measurement group_id="O7" value="16.7" lower_limit="6.81" upper_limit="31.90"/>
                    <measurement group_id="O8" value="0" lower_limit="0.00" upper_limit="12.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.0" lower_limit="13.95" upper_limit="46.22"/>
                    <measurement group_id="O2" value="17.2" lower_limit="7.05" upper_limit="32.89"/>
                    <measurement group_id="O3" value="26.9" lower_limit="13.38" upper_limit="44.68"/>
                    <measurement group_id="O4" value="8.0" lower_limit="1.44" upper_limit="23.10"/>
                    <measurement group_id="O5" value="34.5" lower_limit="20.05" upper_limit="51.43"/>
                    <measurement group_id="O6" value="8.0" lower_limit="1.44" upper_limit="23.10"/>
                    <measurement group_id="O7" value="13.3" lower_limit="4.69" upper_limit="27.96"/>
                    <measurement group_id="O8" value="4.3" lower_limit="0.22" upper_limit="19.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.0" lower_limit="20.24" upper_limit="54.39"/>
                    <measurement group_id="O2" value="13.8" lower_limit="4.85" upper_limit="28.84"/>
                    <measurement group_id="O3" value="26.9" lower_limit="13.38" upper_limit="44.68"/>
                    <measurement group_id="O4" value="8.0" lower_limit="1.44" upper_limit="23.10"/>
                    <measurement group_id="O5" value="51.7" lower_limit="35.20" upper_limit="67.97"/>
                    <measurement group_id="O6" value="8.0" lower_limit="1.44" upper_limit="23.10"/>
                    <measurement group_id="O7" value="10.0" lower_limit="2.78" upper_limit="23.86"/>
                    <measurement group_id="O8" value="4.3" lower_limit="0.22" upper_limit="19.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.0" lower_limit="13.95" upper_limit="46.22"/>
                    <measurement group_id="O2" value="13.8" lower_limit="4.85" upper_limit="28.84"/>
                    <measurement group_id="O3" value="11.5" lower_limit="3.22" upper_limit="27.19"/>
                    <measurement group_id="O4" value="8.0" lower_limit="1.44" upper_limit="23.10"/>
                    <measurement group_id="O5" value="37.9" lower_limit="22.93" upper_limit="54.88"/>
                    <measurement group_id="O6" value="4.0" lower_limit="0.20" upper_limit="17.61"/>
                    <measurement group_id="O7" value="13.3" lower_limit="4.69" upper_limit="27.96"/>
                    <measurement group_id="O8" value="4.3" lower_limit="0.22" upper_limit="19.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="8.23" upper_limit="37.54"/>
                    <measurement group_id="O2" value="3.4" lower_limit="0.18" upper_limit="15.34"/>
                    <measurement group_id="O3" value="15.4" lower_limit="5.43" upper_limit="31.82"/>
                    <measurement group_id="O4" value="4.0" lower_limit="0.20" upper_limit="17.61"/>
                    <measurement group_id="O5" value="27.6" lower_limit="14.53" upper_limit="44.29"/>
                    <measurement group_id="O6" value="8.0" lower_limit="1.44" upper_limit="23.10"/>
                    <measurement group_id="O7" value="10.0" lower_limit="2.78" upper_limit="23.86"/>
                    <measurement group_id="O8" value="4.3" lower_limit="0.22" upper_limit="19.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16</title>
        <description>The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.</description>
        <time_frame>Baseline (Day 1 pre-dose), Weeks 1, 2, 4, 6, 8, 10, 14, 16</time_frame>
        <population>&quot;Number of participants analyzed&quot; represents all participants who received at least 1 dose of investigational product (PF-06700841 or placebo). &quot;Number analyzed&quot; represents all participants who received at least 1 dose of investigational product (PF-06700841 or placebo) and had observed PASI data for each specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 30 mg QD (blinded tablets).</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 60 mg QD Followed by 10 mg QD</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 60 mg QD Followed by Placebo</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of matching placebo QD (blinded tablets).</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841 30 mg QD</title>
            <description>Participants received 12 weeks of blinded PF-06700841 30 mg QD tablets.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841 30 mg QD Followed by 10 mg QD</title>
            <description>Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841 30 mg QD Followed by 100 mg QW</title>
            <description>Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Participants received 12 weeks of blinded matching placebo QD tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16</title>
          <description>The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.</description>
          <population>&quot;Number of participants analyzed&quot; represents all participants who received at least 1 dose of investigational product (PF-06700841 or placebo). &quot;Number analyzed&quot; represents all participants who received at least 1 dose of investigational product (PF-06700841 or placebo) and had observed PASI data for each specified time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="28"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.74" lower_limit="-7.61" upper_limit="-3.86"/>
                    <measurement group_id="O2" value="-4.60" lower_limit="-6.06" upper_limit="-3.14"/>
                    <measurement group_id="O3" value="-5.85" lower_limit="-7.62" upper_limit="-4.08"/>
                    <measurement group_id="O4" value="-5.37" lower_limit="-7.59" upper_limit="-3.15"/>
                    <measurement group_id="O5" value="-3.97" lower_limit="-5.00" upper_limit="-2.95"/>
                    <measurement group_id="O6" value="-4.41" lower_limit="-6.18" upper_limit="-2.64"/>
                    <measurement group_id="O7" value="-3.46" lower_limit="-4.64" upper_limit="-2.28"/>
                    <measurement group_id="O8" value="-1.35" lower_limit="-2.03" upper_limit="-0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="28"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.44" lower_limit="-11.74" upper_limit="-7.15"/>
                    <measurement group_id="O2" value="-8.35" lower_limit="-10.07" upper_limit="-6.63"/>
                    <measurement group_id="O3" value="-10.79" lower_limit="-13.05" upper_limit="-8.52"/>
                    <measurement group_id="O4" value="-9.49" lower_limit="-12.40" upper_limit="-6.58"/>
                    <measurement group_id="O5" value="-7.86" lower_limit="-9.38" upper_limit="-6.35"/>
                    <measurement group_id="O6" value="-7.79" lower_limit="-9.79" upper_limit="-5.79"/>
                    <measurement group_id="O7" value="-7.93" lower_limit="-9.64" upper_limit="-6.22"/>
                    <measurement group_id="O8" value="-2.28" lower_limit="-3.21" upper_limit="-1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="28"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="28"/>
                    <count group_id="O8" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.85" lower_limit="-15.76" upper_limit="-9.94"/>
                    <measurement group_id="O2" value="-12.19" lower_limit="-14.57" upper_limit="-9.81"/>
                    <measurement group_id="O3" value="-14.11" lower_limit="-16.37" upper_limit="-11.86"/>
                    <measurement group_id="O4" value="-13.91" lower_limit="-16.98" upper_limit="-10.85"/>
                    <measurement group_id="O5" value="-11.72" lower_limit="-13.61" upper_limit="-9.83"/>
                    <measurement group_id="O6" value="-12.88" lower_limit="-15.49" upper_limit="-10.27"/>
                    <measurement group_id="O7" value="-13.06" lower_limit="-15.58" upper_limit="-10.53"/>
                    <measurement group_id="O8" value="-4.02" lower_limit="-6.04" upper_limit="-2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="28"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="27"/>
                    <count group_id="O8" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.00" lower_limit="-18.30" upper_limit="-11.71"/>
                    <measurement group_id="O2" value="-12.12" lower_limit="-14.53" upper_limit="-9.71"/>
                    <measurement group_id="O3" value="-15.00" lower_limit="-17.35" upper_limit="-12.66"/>
                    <measurement group_id="O4" value="-13.85" lower_limit="-16.62" upper_limit="-11.08"/>
                    <measurement group_id="O5" value="-14.30" lower_limit="-16.24" upper_limit="-12.36"/>
                    <measurement group_id="O6" value="-14.33" lower_limit="-17.47" upper_limit="-11.19"/>
                    <measurement group_id="O7" value="-14.17" lower_limit="-16.92" upper_limit="-11.41"/>
                    <measurement group_id="O8" value="-5.52" lower_limit="-7.58" upper_limit="-3.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="21"/>
                    <count group_id="O7" value="27"/>
                    <count group_id="O8" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.94" lower_limit="-19.40" upper_limit="-12.49"/>
                    <measurement group_id="O2" value="-11.09" lower_limit="-12.90" upper_limit="-9.27"/>
                    <measurement group_id="O3" value="-14.97" lower_limit="-17.66" upper_limit="-12.27"/>
                    <measurement group_id="O4" value="-12.87" lower_limit="-15.69" upper_limit="-10.04"/>
                    <measurement group_id="O5" value="-15.82" lower_limit="-17.81" upper_limit="-13.84"/>
                    <measurement group_id="O6" value="-14.27" lower_limit="-17.51" upper_limit="-11.03"/>
                    <measurement group_id="O7" value="-13.83" lower_limit="-16.79" upper_limit="-10.87"/>
                    <measurement group_id="O8" value="-6.56" lower_limit="-8.61" upper_limit="-4.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="21"/>
                    <count group_id="O7" value="27"/>
                    <count group_id="O8" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.54" lower_limit="-20.54" upper_limit="-12.54"/>
                    <measurement group_id="O2" value="-9.89" lower_limit="-12.16" upper_limit="-7.61"/>
                    <measurement group_id="O3" value="-15.52" lower_limit="-18.09" upper_limit="-12.96"/>
                    <measurement group_id="O4" value="-11.64" lower_limit="-14.92" upper_limit="-8.37"/>
                    <measurement group_id="O5" value="-16.65" lower_limit="-18.64" upper_limit="-14.66"/>
                    <measurement group_id="O6" value="-14.98" lower_limit="-18.43" upper_limit="-11.53"/>
                    <measurement group_id="O7" value="-12.97" lower_limit="-16.19" upper_limit="-9.74"/>
                    <measurement group_id="O8" value="-6.78" lower_limit="-9.20" upper_limit="-4.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="19"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.47" lower_limit="-19.88" upper_limit="-11.06"/>
                    <measurement group_id="O2" value="-8.11" lower_limit="-10.69" upper_limit="-5.53"/>
                    <measurement group_id="O3" value="-13.31" lower_limit="-16.73" upper_limit="-9.89"/>
                    <measurement group_id="O4" value="-9.45" lower_limit="-12.96" upper_limit="-5.94"/>
                    <measurement group_id="O5" value="-16.14" lower_limit="-18.16" upper_limit="-14.12"/>
                    <measurement group_id="O6" value="-10.44" lower_limit="-13.33" upper_limit="-7.55"/>
                    <measurement group_id="O7" value="-11.03" lower_limit="-14.61" upper_limit="-7.44"/>
                    <measurement group_id="O8" value="-6.98" lower_limit="-9.81" upper_limit="-4.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="18"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.16" lower_limit="-18.68" upper_limit="-9.64"/>
                    <measurement group_id="O2" value="-6.59" lower_limit="-9.09" upper_limit="-4.09"/>
                    <measurement group_id="O3" value="-13.00" lower_limit="-16.60" upper_limit="-9.40"/>
                    <measurement group_id="O4" value="-7.83" lower_limit="-11.56" upper_limit="-4.11"/>
                    <measurement group_id="O5" value="-14.38" lower_limit="-16.74" upper_limit="-12.01"/>
                    <measurement group_id="O6" value="-9.62" lower_limit="-13.08" upper_limit="-6.16"/>
                    <measurement group_id="O7" value="-9.13" lower_limit="-13.94" upper_limit="-4.33"/>
                    <measurement group_id="O8" value="-6.76" lower_limit="-9.80" upper_limit="-3.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16</title>
        <description>The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.</description>
        <time_frame>Baseline (Day 1 pre-dose), Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16</time_frame>
        <population>&quot;Number of participants analyzed&quot; represents all participants who received at least 1 dose of investigational product (PF-06700841 or placebo). &quot;Number analyzed&quot; represents all participants who received at least 1 dose of investigational product (PF-06700841 or placebo) and had observed PASI data for each specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 30 mg QD (blinded tablets).</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 60 mg QD Followed by 10 mg QD</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 60 mg QD Followed by Placebo</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of matching placebo QD (blinded tablets).</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841 30 mg QD</title>
            <description>Participants received 12 weeks of blinded PF-06700841 30 mg QD tablets.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841 30 mg QD Followed by 10 mg QD</title>
            <description>Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841 30 mg QD Followed by 100 mg QW</title>
            <description>Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Participants received 12 weeks of blinded matching placebo QD tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16</title>
          <description>The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.</description>
          <population>&quot;Number of participants analyzed&quot; represents all participants who received at least 1 dose of investigational product (PF-06700841 or placebo). &quot;Number analyzed&quot; represents all participants who received at least 1 dose of investigational product (PF-06700841 or placebo) and had observed PASI data for each specified time point.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="28"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.70" lower_limit="-33.80" upper_limit="-19.60"/>
                    <measurement group_id="O2" value="-24.66" lower_limit="-33.24" upper_limit="-16.08"/>
                    <measurement group_id="O3" value="-30.25" lower_limit="-39.07" upper_limit="-21.44"/>
                    <measurement group_id="O4" value="-23.33" lower_limit="-30.84" upper_limit="-15.82"/>
                    <measurement group_id="O5" value="-20.92" lower_limit="-26.82" upper_limit="-15.01"/>
                    <measurement group_id="O6" value="-17.50" lower_limit="-23.91" upper_limit="-11.10"/>
                    <measurement group_id="O7" value="-15.42" lower_limit="-20.68" upper_limit="-10.16"/>
                    <measurement group_id="O8" value="-6.90" lower_limit="-10.50" upper_limit="-3.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="28"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-43.66" lower_limit="-52.81" upper_limit="-34.52"/>
                    <measurement group_id="O2" value="-44.17" lower_limit="-52.75" upper_limit="-35.59"/>
                    <measurement group_id="O3" value="-54.27" lower_limit="-64.17" upper_limit="-44.36"/>
                    <measurement group_id="O4" value="-42.58" lower_limit="-51.17" upper_limit="-33.98"/>
                    <measurement group_id="O5" value="-40.89" lower_limit="-47.94" upper_limit="-33.83"/>
                    <measurement group_id="O6" value="-32.46" lower_limit="-39.75" upper_limit="-25.16"/>
                    <measurement group_id="O7" value="-35.89" lower_limit="-42.69" upper_limit="-29.09"/>
                    <measurement group_id="O8" value="-12.81" lower_limit="-18.29" upper_limit="-7.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="28"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="28"/>
                    <count group_id="O8" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-57.16" lower_limit="-67.35" upper_limit="-46.97"/>
                    <measurement group_id="O2" value="-63.02" lower_limit="-72.12" upper_limit="-53.91"/>
                    <measurement group_id="O3" value="-72.41" lower_limit="-82.31" upper_limit="-62.51"/>
                    <measurement group_id="O4" value="-64.71" lower_limit="-72.81" upper_limit="-56.61"/>
                    <measurement group_id="O5" value="-60.76" lower_limit="-68.38" upper_limit="-53.14"/>
                    <measurement group_id="O6" value="-53.93" lower_limit="-62.59" upper_limit="-45.28"/>
                    <measurement group_id="O7" value="-58.99" lower_limit="-67.94" upper_limit="-50.03"/>
                    <measurement group_id="O8" value="-25.17" lower_limit="-34.24" upper_limit="-16.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="28"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="27"/>
                    <count group_id="O8" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-66.07" lower_limit="-76.06" upper_limit="-56.08"/>
                    <measurement group_id="O2" value="-63.31" lower_limit="-73.99" upper_limit="-52.62"/>
                    <measurement group_id="O3" value="-75.96" lower_limit="-84.68" upper_limit="-67.25"/>
                    <measurement group_id="O4" value="-65.06" lower_limit="-74.15" upper_limit="-55.97"/>
                    <measurement group_id="O5" value="-73.91" lower_limit="-80.62" upper_limit="-67.19"/>
                    <measurement group_id="O6" value="-58.57" lower_limit="-66.76" upper_limit="-50.37"/>
                    <measurement group_id="O7" value="-63.17" lower_limit="-72.37" upper_limit="-53.96"/>
                    <measurement group_id="O8" value="-33.49" lower_limit="-44.16" upper_limit="-22.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="21"/>
                    <count group_id="O7" value="27"/>
                    <count group_id="O8" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-70.11" lower_limit="-80.95" upper_limit="-59.27"/>
                    <measurement group_id="O2" value="-62.25" lower_limit="-72.42" upper_limit="-52.07"/>
                    <measurement group_id="O3" value="-77.05" lower_limit="-86.69" upper_limit="-67.41"/>
                    <measurement group_id="O4" value="-59.88" lower_limit="-69.78" upper_limit="-49.97"/>
                    <measurement group_id="O5" value="-81.04" lower_limit="-86.69" upper_limit="-75.40"/>
                    <measurement group_id="O6" value="-58.32" lower_limit="-66.39" upper_limit="-50.25"/>
                    <measurement group_id="O7" value="-61.38" lower_limit="-71.80" upper_limit="-50.96"/>
                    <measurement group_id="O8" value="-37.76" lower_limit="-47.73" upper_limit="-27.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="21"/>
                    <count group_id="O7" value="27"/>
                    <count group_id="O8" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-70.72" lower_limit="-83.32" upper_limit="-58.12"/>
                    <measurement group_id="O2" value="-57.55" lower_limit="-69.11" upper_limit="-46.00"/>
                    <measurement group_id="O3" value="-78.46" lower_limit="-85.82" upper_limit="-71.09"/>
                    <measurement group_id="O4" value="-53.81" lower_limit="-64.41" upper_limit="-43.22"/>
                    <measurement group_id="O5" value="-84.82" lower_limit="-89.50" upper_limit="-80.15"/>
                    <measurement group_id="O6" value="-61.23" lower_limit="-69.29" upper_limit="-53.17"/>
                    <measurement group_id="O7" value="-57.24" lower_limit="-68.80" upper_limit="-45.69"/>
                    <measurement group_id="O8" value="-39.68" lower_limit="-50.92" upper_limit="-28.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="19"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-71.94" lower_limit="-84.67" upper_limit="-59.21"/>
                    <measurement group_id="O2" value="-58.52" lower_limit="-69.38" upper_limit="-47.67"/>
                    <measurement group_id="O3" value="-74.42" lower_limit="-84.98" upper_limit="-63.87"/>
                    <measurement group_id="O4" value="-51.49" lower_limit="-63.21" upper_limit="-39.78"/>
                    <measurement group_id="O5" value="-88.68" lower_limit="-93.13" upper_limit="-84.22"/>
                    <measurement group_id="O6" value="-57.81" lower_limit="-68.52" upper_limit="-47.10"/>
                    <measurement group_id="O7" value="-58.57" lower_limit="-70.05" upper_limit="-47.09"/>
                    <measurement group_id="O8" value="-40.27" lower_limit="-52.68" upper_limit="-27.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="19"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-64.15" lower_limit="-78.24" upper_limit="-50.05"/>
                    <measurement group_id="O2" value="-47.87" lower_limit="-62.17" upper_limit="-33.56"/>
                    <measurement group_id="O3" value="-63.20" lower_limit="-74.36" upper_limit="-52.05"/>
                    <measurement group_id="O4" value="-44.30" lower_limit="-57.51" upper_limit="-31.09"/>
                    <measurement group_id="O5" value="-83.39" lower_limit="-89.74" upper_limit="-77.04"/>
                    <measurement group_id="O6" value="-47.84" lower_limit="-60.18" upper_limit="-35.49"/>
                    <measurement group_id="O7" value="-47.52" lower_limit="-59.86" upper_limit="-35.18"/>
                    <measurement group_id="O8" value="-39.48" lower_limit="-52.09" upper_limit="-26.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="18"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-57.28" lower_limit="-72.02" upper_limit="-42.54"/>
                    <measurement group_id="O2" value="-38.48" lower_limit="-51.85" upper_limit="-25.10"/>
                    <measurement group_id="O3" value="-60.56" lower_limit="-72.71" upper_limit="-48.42"/>
                    <measurement group_id="O4" value="-36.63" lower_limit="-51.43" upper_limit="-21.83"/>
                    <measurement group_id="O5" value="-74.18" lower_limit="-83.22" upper_limit="-65.15"/>
                    <measurement group_id="O6" value="-44.58" lower_limit="-58.96" upper_limit="-30.19"/>
                    <measurement group_id="O7" value="-42.29" lower_limit="-59.96" upper_limit="-24.63"/>
                    <measurement group_id="O8" value="-38.79" lower_limit="-51.92" upper_limit="-25.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
        <description>An AE (non-serious and serious) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or an important medical event. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent.</description>
        <time_frame>From first dose of study treatment (Day 1) up to Week 20</time_frame>
        <population>All participants who received at least 1 dose of investigational product (PF-06700841 or placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 30 mg QD (blinded tablets).</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 60 mg QD Followed by 10 mg QD</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 60 mg QD Followed by Placebo</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of matching placebo QD (blinded tablets).</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841 30 mg QD</title>
            <description>Participants received 12 weeks of blinded PF-06700841 30 mg QD tablets.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841 30 mg QD Followed by 10 mg QD</title>
            <description>Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841 30 mg QD Followed by 100 mg QW</title>
            <description>Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Participants received 12 weeks of blinded matching placebo QD tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
          <description>An AE (non-serious and serious) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or an important medical event. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent.</description>
          <population>All participants who received at least 1 dose of investigational product (PF-06700841 or placebo).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment-emergent AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="21"/>
                    <measurement group_id="O6" value="16"/>
                    <measurement group_id="O7" value="23"/>
                    <measurement group_id="O8" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-emergent SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Discontinued From the Study Due to Treatment-Emergent AEs</title>
        <description>The number of participants who discontinued from the study due to treatment-emergent AEs is presented. Note for data reported under this Outcome Measure: Per sponsor reporting standard, pregnancy was counted as AE for AE data tables while it was counted separately in the disposition data table (Participant Flow Module).</description>
        <time_frame>From first dose of study treatment (Day 1) up to Week 20</time_frame>
        <population>All participants who received at least 1 dose of investigational product (PF-06700841 or placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 30 mg QD (blinded tablets).</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 60 mg QD Followed by 10 mg QD</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 60 mg QD Followed by Placebo</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of matching placebo QD (blinded tablets).</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841 30 mg QD</title>
            <description>Participants received 12 weeks of blinded PF-06700841 30 mg QD tablets.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841 30 mg QD Followed by 10 mg QD</title>
            <description>Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841 30 mg QD Followed by 100 mg QW</title>
            <description>Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Participants received 12 weeks of blinded matching placebo QD tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Discontinued From the Study Due to Treatment-Emergent AEs</title>
          <description>The number of participants who discontinued from the study due to treatment-emergent AEs is presented. Note for data reported under this Outcome Measure: Per sponsor reporting standard, pregnancy was counted as AE for AE data tables while it was counted separately in the disposition data table (Participant Flow Module).</description>
          <population>All participants who received at least 1 dose of investigational product (PF-06700841 or placebo).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Blood Lipid Level at Weeks 4 and 12</title>
        <description>Lipid panel included low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, total cholesterol, and triglycerides.</description>
        <time_frame>Baseline (Day 1 pre-dose), Weeks 4 and 12</time_frame>
        <population>&quot;Number of participants analyzed&quot; represents all participants who received at least 1 dose of investigational product (PF-06700841 or placebo). &quot;Number analyzed&quot; represents all participants who received at least 1 dose of investigational product (PF-06700841 or placebo) and had data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 30 mg QD (blinded tablets).</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 60 mg QD Followed by 10 mg QD</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 60 mg QD Followed by Placebo</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of matching placebo QD (blinded tablets).</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841 30 mg QD</title>
            <description>Participants received 12 weeks of blinded PF-06700841 30 mg QD tablets.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841 30 mg QD Followed by 10 mg QD</title>
            <description>Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841 30 mg QD Followed by 100 mg QW</title>
            <description>Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Participants received 12 weeks of blinded matching placebo QD tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Blood Lipid Level at Weeks 4 and 12</title>
          <description>Lipid panel included low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, total cholesterol, and triglycerides.</description>
          <population>&quot;Number of participants analyzed&quot; represents all participants who received at least 1 dose of investigational product (PF-06700841 or placebo). &quot;Number analyzed&quot; represents all participants who received at least 1 dose of investigational product (PF-06700841 or placebo) and had data for each specified category.</population>
          <units>milligram per deciliter (mg/dL)</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LDL Cholesterol, Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="23"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="25"/>
                    <count group_id="O8" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.91" lower_limit="7.95" upper_limit="23.86"/>
                    <measurement group_id="O2" value="11.27" lower_limit="4.31" upper_limit="18.23"/>
                    <measurement group_id="O3" value="15.00" lower_limit="-0.63" upper_limit="30.63"/>
                    <measurement group_id="O4" value="15.88" lower_limit="6.63" upper_limit="25.12"/>
                    <measurement group_id="O5" value="8.96" lower_limit="0.99" upper_limit="16.92"/>
                    <measurement group_id="O6" value="-2.21" lower_limit="-11.04" upper_limit="6.63"/>
                    <measurement group_id="O7" value="7.60" lower_limit="-4.39" upper_limit="19.59"/>
                    <measurement group_id="O8" value="-6.28" lower_limit="-10.56" upper_limit="-2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Cholesterol, Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="20"/>
                    <count group_id="O6" value="18"/>
                    <count group_id="O7" value="22"/>
                    <count group_id="O8" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.71" lower_limit="1.04" upper_limit="16.39"/>
                    <measurement group_id="O2" value="6.00" lower_limit="-4.73" upper_limit="16.73"/>
                    <measurement group_id="O3" value="-0.74" lower_limit="-11.67" upper_limit="10.20"/>
                    <measurement group_id="O4" value="6.85" lower_limit="-2.06" upper_limit="15.76"/>
                    <measurement group_id="O5" value="14.10" lower_limit="6.63" upper_limit="21.57"/>
                    <measurement group_id="O6" value="-5.33" lower_limit="-18.24" upper_limit="7.57"/>
                    <measurement group_id="O7" value="3.95" lower_limit="-7.79" upper_limit="15.70"/>
                    <measurement group_id="O8" value="-4.00" lower_limit="-9.71" upper_limit="1.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL Cholesterol, Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="28"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="28"/>
                    <count group_id="O8" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.09" lower_limit="8.07" upper_limit="16.11"/>
                    <measurement group_id="O2" value="9.14" lower_limit="5.84" upper_limit="12.45"/>
                    <measurement group_id="O3" value="10.92" lower_limit="7.38" upper_limit="14.46"/>
                    <measurement group_id="O4" value="8.58" lower_limit="5.84" upper_limit="11.33"/>
                    <measurement group_id="O5" value="6.36" lower_limit="3.91" upper_limit="8.80"/>
                    <measurement group_id="O6" value="6.76" lower_limit="2.93" upper_limit="10.59"/>
                    <measurement group_id="O7" value="9.39" lower_limit="7.03" upper_limit="11.75"/>
                    <measurement group_id="O8" value="0.00" lower_limit="-5.14" upper_limit="5.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL Cholesterol, Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="19"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" lower_limit="1.29" upper_limit="8.71"/>
                    <measurement group_id="O2" value="5.48" lower_limit="1.66" upper_limit="9.29"/>
                    <measurement group_id="O3" value="2.48" lower_limit="-0.31" upper_limit="5.26"/>
                    <measurement group_id="O4" value="-0.24" lower_limit="-2.55" upper_limit="2.08"/>
                    <measurement group_id="O5" value="4.74" lower_limit="1.30" upper_limit="8.18"/>
                    <measurement group_id="O6" value="4.37" lower_limit="1.04" upper_limit="7.70"/>
                    <measurement group_id="O7" value="2.88" lower_limit="-0.24" upper_limit="5.99"/>
                    <measurement group_id="O8" value="-2.73" lower_limit="-6.32" upper_limit="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Cholesterol, Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="28"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="28"/>
                    <count group_id="O8" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.39" lower_limit="24.01" upper_limit="44.77"/>
                    <measurement group_id="O2" value="29.46" lower_limit="18.68" upper_limit="40.25"/>
                    <measurement group_id="O3" value="31.32" lower_limit="15.20" upper_limit="47.44"/>
                    <measurement group_id="O4" value="26.33" lower_limit="15.85" upper_limit="36.82"/>
                    <measurement group_id="O5" value="15.14" lower_limit="-0.16" upper_limit="30.45"/>
                    <measurement group_id="O6" value="10.36" lower_limit="-1.70" upper_limit="22.42"/>
                    <measurement group_id="O7" value="14.00" lower_limit="0.14" upper_limit="27.86"/>
                    <measurement group_id="O8" value="-4.42" lower_limit="-10.90" upper_limit="2.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Cholesterol, Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="19"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.50" lower_limit="9.95" upper_limit="29.05"/>
                    <measurement group_id="O2" value="15.67" lower_limit="2.74" upper_limit="28.59"/>
                    <measurement group_id="O3" value="-1.86" lower_limit="-13.78" upper_limit="10.07"/>
                    <measurement group_id="O4" value="7.05" lower_limit="-3.25" upper_limit="17.35"/>
                    <measurement group_id="O5" value="20.37" lower_limit="3.06" upper_limit="37.68"/>
                    <measurement group_id="O6" value="0.68" lower_limit="-14.51" upper_limit="15.87"/>
                    <measurement group_id="O7" value="4.33" lower_limit="-8.86" upper_limit="17.53"/>
                    <measurement group_id="O8" value="-6.40" lower_limit="-13.68" upper_limit="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides, Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="28"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="28"/>
                    <count group_id="O8" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.74" lower_limit="-8.43" upper_limit="77.91"/>
                    <measurement group_id="O2" value="29.68" lower_limit="10.42" upper_limit="48.94"/>
                    <measurement group_id="O3" value="8.04" lower_limit="-20.07" upper_limit="36.15"/>
                    <measurement group_id="O4" value="8.92" lower_limit="-21.83" upper_limit="39.66"/>
                    <measurement group_id="O5" value="-65.11" lower_limit="-204.94" upper_limit="74.72"/>
                    <measurement group_id="O6" value="19.60" lower_limit="-3.04" upper_limit="42.24"/>
                    <measurement group_id="O7" value="-59.75" lower_limit="-157.79" upper_limit="38.29"/>
                    <measurement group_id="O8" value="15.26" lower_limit="-11.07" upper_limit="41.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides, Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="19"/>
                    <count group_id="O7" value="24"/>
                    <count group_id="O8" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.86" lower_limit="-4.68" upper_limit="60.41"/>
                    <measurement group_id="O2" value="48.33" lower_limit="-32.67" upper_limit="129.34"/>
                    <measurement group_id="O3" value="-85.00" lower_limit="-213.81" upper_limit="43.81"/>
                    <measurement group_id="O4" value="2.67" lower_limit="-27.36" upper_limit="32.70"/>
                    <measurement group_id="O5" value="-18.96" lower_limit="-198.51" upper_limit="160.59"/>
                    <measurement group_id="O6" value="6.32" lower_limit="-19.21" upper_limit="31.84"/>
                    <measurement group_id="O7" value="-67.79" lower_limit="-185.53" upper_limit="49.95"/>
                    <measurement group_id="O8" value="1.87" lower_limit="-24.28" upper_limit="28.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Post-Baseline Laboratory Test Abnormalities</title>
        <description>Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology (hemoglobin, hematocrit, erythrocytes, reticulocytes, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils, monocytes, activated partial thromboplastin time, prothrombin time [PT], PT/international normalized ratio; chemistry (total bilirubin, direct bilirubin, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, alkaline phosphatase, protein, albumin, urea nitrogen, creatinine, urate, total cholesterol, LDL and HDL cholesterol, triglycerides, calcium, sodium, potassium, chloride, bicarbonate, glucose, creatine kinase, Cystatin C, glomerular filtration rate; urinalysis (pH, urine glucose, ketones, urine protein, urine hemoglobin, nitrites, leukocyte esterase, urine erythrocytes, urine leukocytes, hyaline casts, bacteria, choriogonadotropin beta).</description>
        <time_frame>From first dose of study treatment (Day 1) up to Week 16</time_frame>
        <population>All participants who received at least 1 dose of investigational product (PF-06700841 or placebo) and had post-baseline laboratory data.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 30 mg QD (blinded tablets).</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 60 mg QD Followed by 10 mg QD</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 60 mg QD Followed by Placebo</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of matching placebo QD (blinded tablets).</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841 30 mg QD</title>
            <description>Participants received 12 weeks of blinded PF-06700841 30 mg QD tablets.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841 30 mg QD Followed by 10 mg QD</title>
            <description>Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841 30 mg QD Followed by 100 mg QW</title>
            <description>Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Participants received 12 weeks of blinded matching placebo QD tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Post-Baseline Laboratory Test Abnormalities</title>
          <description>Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology (hemoglobin, hematocrit, erythrocytes, reticulocytes, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils, monocytes, activated partial thromboplastin time, prothrombin time [PT], PT/international normalized ratio; chemistry (total bilirubin, direct bilirubin, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, alkaline phosphatase, protein, albumin, urea nitrogen, creatinine, urate, total cholesterol, LDL and HDL cholesterol, triglycerides, calcium, sodium, potassium, chloride, bicarbonate, glucose, creatine kinase, Cystatin C, glomerular filtration rate; urinalysis (pH, urine glucose, ketones, urine protein, urine hemoglobin, nitrites, leukocyte esterase, urine erythrocytes, urine leukocytes, hyaline casts, bacteria, choriogonadotropin beta).</description>
          <population>All participants who received at least 1 dose of investigational product (PF-06700841 or placebo) and had post-baseline laboratory data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="28"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="21"/>
                    <measurement group_id="O6" value="20"/>
                    <measurement group_id="O7" value="18"/>
                    <measurement group_id="O8" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Post-Baseline Vital Sign Abnormalities</title>
        <description>Vital signs categorical summarization criteria: 1) sitting systolic blood pressure (SBP) &lt;90 millimeters of mercury (mmHg); 2) sitting diastolic blood pressure (DBP) &lt;50 mmHg; 3) sitting pulse rate &lt;40 or &gt;120 beats per minute (bpm); 4) change from baseline (increase or decrease) in sitting DBP greater than or equal to (&gt;=) 20 mmHg; 5) change from baseline (increase or decrease) in sitting SBP &gt;=30 mmHg.</description>
        <time_frame>From first dose of study treatment (Day 1) up to Week 16</time_frame>
        <population>All participants who received at least 1 dose of investigational product (PF-06700841 or placebo) and had post-baseline vital signs data.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 30 mg QD (blinded tablets).</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 60 mg QD Followed by 10 mg QD</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 60 mg QD Followed by Placebo</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of matching placebo QD (blinded tablets).</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841 30 mg QD</title>
            <description>Participants received 12 weeks of blinded PF-06700841 30 mg QD tablets.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841 30 mg QD Followed by 10 mg QD</title>
            <description>Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841 30 mg QD Followed by 100 mg QW</title>
            <description>Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Participants received 12 weeks of blinded matching placebo QD tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Post-Baseline Vital Sign Abnormalities</title>
          <description>Vital signs categorical summarization criteria: 1) sitting systolic blood pressure (SBP) &lt;90 millimeters of mercury (mmHg); 2) sitting diastolic blood pressure (DBP) &lt;50 mmHg; 3) sitting pulse rate &lt;40 or &gt;120 beats per minute (bpm); 4) change from baseline (increase or decrease) in sitting DBP greater than or equal to (&gt;=) 20 mmHg; 5) change from baseline (increase or decrease) in sitting SBP &gt;=30 mmHg.</description>
          <population>All participants who received at least 1 dose of investigational product (PF-06700841 or placebo) and had post-baseline vital signs data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="28"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sitting DBP &lt;50 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitting DBP increase &gt;=20 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitting DBP decrease &gt;=20 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitting SBP &lt;90 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitting SBP increase &gt;=30 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitting SBP decrease &gt;=30 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitting pulse rate &lt;40 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitting pulse rate &gt;120 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities</title>
        <description>ECG categorical summarization criteria: 1) QRS duration (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): &gt;=140 milliseconds (msec), &gt;=50% change from baseline; 2) PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): &gt;=300 msec, &gt;=25% change when baseline is &gt; 200 msec or &gt;=50% change when baseline is less than or equal to (&lt;=) 200 msec; 3) QT interval (time from ECG Q wave to the end of the T wave corresponding to electrical systole): absolute value of &gt;=500 msec; 4) QTc interval (QT corrected for heart rate): absolute value of 450 to &lt;480 msec, 480 to &lt;500 msec, &gt;=500 msec; a change from baseline of 30 to &lt;60 msec or &gt;=60 msec.</description>
        <time_frame>From first dose of study treatment (Day 1) up to Week 16</time_frame>
        <population>All participants who received at least 1 dose of investigational product (PF-06700841 or placebo) and had post-baseline ECG data.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 30 mg QD (blinded tablets).</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 60 mg QD Followed by 10 mg QD</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 60 mg QD Followed by Placebo</title>
            <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of matching placebo QD (blinded tablets).</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841 30 mg QD</title>
            <description>Participants received 12 weeks of blinded PF-06700841 30 mg QD tablets.</description>
          </group>
          <group group_id="O6">
            <title>PF-06700841 30 mg QD Followed by 10 mg QD</title>
            <description>Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841 30 mg QD Followed by 100 mg QW</title>
            <description>Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Participants received 12 weeks of blinded matching placebo QD tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities</title>
          <description>ECG categorical summarization criteria: 1) QRS duration (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): &gt;=140 milliseconds (msec), &gt;=50% change from baseline; 2) PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): &gt;=300 msec, &gt;=25% change when baseline is &gt; 200 msec or &gt;=50% change when baseline is less than or equal to (&lt;=) 200 msec; 3) QT interval (time from ECG Q wave to the end of the T wave corresponding to electrical systole): absolute value of &gt;=500 msec; 4) QTc interval (QT corrected for heart rate): absolute value of 450 to &lt;480 msec, 480 to &lt;500 msec, &gt;=500 msec; a change from baseline of 30 to &lt;60 msec or &gt;=60 msec.</description>
          <population>All participants who received at least 1 dose of investigational product (PF-06700841 or placebo) and had post-baseline ECG data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="28"/>
                <count group_id="O6" value="25"/>
                <count group_id="O7" value="28"/>
                <count group_id="O8" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR interval &gt;=300 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>%Change in PR interval &gt;=25/50%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS duration &gt;=140 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>%Change in QRS duration &gt;=50%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval &gt;=500 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTc &gt;=450 to &lt;480 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTc &gt;=480 to &lt;500 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTc &gt;=500 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTc change &gt;=30 to &lt;60 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTc change &gt;=60 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose of study treatment up to 20 weeks</time_frame>
      <desc>The same event may appear as both an AE and an SAE. However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as non-serious in another participant, or 1 participant may have experienced both a serious and non-serious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD</title>
          <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 30 mg QD (blinded tablets).</description>
        </group>
        <group group_id="E2">
          <title>PF-06700841 60 mg QD Followed by 10 mg QD</title>
          <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).</description>
        </group>
        <group group_id="E3">
          <title>PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)</title>
          <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).</description>
        </group>
        <group group_id="E4">
          <title>PF-06700841 60 mg QD Followed by Placebo</title>
          <description>Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of matching placebo QD (blinded tablets).</description>
        </group>
        <group group_id="E5">
          <title>PF-06700841 30 mg QD</title>
          <description>Participants received 12 weeks of blinded PF-06700841 30 mg QD tablets.</description>
        </group>
        <group group_id="E6">
          <title>PF-06700841 30 mg QD Followed by 10 mg QD</title>
          <description>Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).</description>
        </group>
        <group group_id="E7">
          <title>PF-06700841 30 mg QD Followed by 100 mg QW</title>
          <description>Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).</description>
        </group>
        <group group_id="E8">
          <title>Placebo</title>
          <description>Participants received 12 weeks of blinded matching placebo QD tablets.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v20.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA v20.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="29"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="25"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E7" events="4" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E7" events="5" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E5" events="6" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02969018
org study id: B7931004
secondary id: 2016-004049-96
nct id: NCT02969018
lead sponsor: 
has dmc: No
The purpose of this study is to determine whether PF-06700841 is safe and effective in the
      treatment of chronic plaque psoriasis.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
measure: Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12
time frame: Baseline (Day 1 pre-dose), Week 12
description: The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percentage of body surface area (BSA) affected. In each area, the sum of the severity rating scores for erythema, induration and scaling is multiplied by the score representing the percentage of this area involved by psoriasis, multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4). The sum of the numbers obtained for each of the four body areas is the PASI. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.
measure: Percentage of Participants Achieving a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 12
time frame: Week 12
description: A PASI75 response is a 75% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.
measure: Change From Baseline in PASI Scores at Week 4 by Induction Dose
time frame: Baseline (Day 1 pre-dose), Week 4
description: Change from baseline in PASI scores at Week 4 was presented by induction dose (ie, PF-06700841 60 mg QD, 30 mg QD, and placebo). The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.
measure: Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16
time frame: Weeks 1, 2, 4, 6, 8, 10, 14, 16
description: A PASI75 response is a 75% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.
measure: Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16
time frame: Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16
description: A PASI50 response is a 50% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.
measure: Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16
time frame: Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16
description: A PASI90 response is a 90% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.
measure: Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16
time frame: Baseline (Day 1 pre-dose), Weeks 1, 2, 4, 6, 8, 10, 14, 16
description: The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.
measure: Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16
time frame: Baseline (Day 1 pre-dose), Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16
description: The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.
measure: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
time frame: From first dose of study treatment (Day 1) up to Week 20
description: An AE (non-serious and serious) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or an important medical event. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent.
measure: Number of Participants Who Discontinued From the Study Due to Treatment-Emergent AEs
time frame: From first dose of study treatment (Day 1) up to Week 20
description: The number of participants who discontinued from the study due to treatment-emergent AEs is presented. Note for data reported under this Outcome Measure: Per sponsor reporting standard, pregnancy was counted as AE for AE data tables while it was counted separately in the disposition data table (Participant Flow Module).
measure: Change From Baseline in Blood Lipid Level at Weeks 4 and 12
time frame: Baseline (Day 1 pre-dose), Weeks 4 and 12
description: Lipid panel included low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, total cholesterol, and triglycerides.
measure: Number of Participants With Any Post-Baseline Laboratory Test Abnormalities
time frame: From first dose of study treatment (Day 1) up to Week 16
description: Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology (hemoglobin, hematocrit, erythrocytes, reticulocytes, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils, monocytes, activated partial thromboplastin time, prothrombin time [PT], PT/international normalized ratio; chemistry (total bilirubin, direct bilirubin, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, alkaline phosphatase, protein, albumin, urea nitrogen, creatinine, urate, total cholesterol, LDL and HDL cholesterol, triglycerides, calcium, sodium, potassium, chloride, bicarbonate, glucose, creatine kinase, Cystatin C, glomerular filtration rate; urinalysis (pH, urine glucose, ketones, urine protein, urine hemoglobin, nitrites, leukocyte esterase, urine erythrocytes, urine leukocytes, hyaline casts, bacteria, choriogonadotropin beta).
measure: Number of Participants With Post-Baseline Vital Sign Abnormalities
time frame: From first dose of study treatment (Day 1) up to Week 16
description: Vital signs categorical summarization criteria: 1) sitting systolic blood pressure (SBP) <90 millimeters of mercury (mmHg); 2) sitting diastolic blood pressure (DBP) <50 mmHg; 3) sitting pulse rate <40 or >120 beats per minute (bpm); 4) change from baseline (increase or decrease) in sitting DBP greater than or equal to (>=) 20 mmHg; 5) change from baseline (increase or decrease) in sitting SBP >=30 mmHg.
measure: Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities
time frame: From first dose of study treatment (Day 1) up to Week 16
description: ECG categorical summarization criteria: 1) QRS duration (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): >=140 milliseconds (msec), >=50% change from baseline; 2) PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): >=300 msec, >=25% change when baseline is > 200 msec or >=50% change when baseline is less than or equal to (<=) 200 msec; 3) QT interval (time from ECG Q wave to the end of the T wave corresponding to electrical systole): absolute value of >=500 msec; 4) QTc interval (QT corrected for heart rate): absolute value of 450 to <480 msec, 480 to <500 msec, >=500 msec; a change from baseline of 30 to <60 msec or >=60 msec.
arm group label: PF-06700841 60 mg followed by 30 mg once daily
arm group type: Experimental
description: 4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of 30 mg PF-06700841 once daily
arm group label: PF-06700841 60 mg followed by 10 mg once daily
arm group type: Experimental
description: 4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of 10 mg PF-06700841 once daily
arm group label: PF-06700841 60mg once daily followed by 100mg once weekly
arm group type: Experimental
description: 4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of 100 mg PF-06700841 once weekly
arm group label: PF-06700841 60mg once daily followed by placebo once daily
arm group type: Experimental
description: 4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of placebo once daily
arm group label: PF-06700841 30mg once daily
arm group type: Experimental
description: 4 week induction with 30 mg PF-06700841 once daily followed by 8 week chronic administration of 30 mg PF-06700841 once daily
arm group label: PF-06700841 30mg once daily followed by 10mg once daily
arm group type: Experimental
description: 4 week induction with 30 mg PF-06700841 once daily, followed by 8 week chronic administration of 10 mg PF-06700841 once daily
arm group label: PF-06700841 30mg once daily followed by 100mg once weekly
arm group type: Experimental
description: 4 week induction with 30 mg PF-06700841 once daily, followed by 8 week chronic administration of 100 mg PF-06700841 once weekly
arm group label: Placebo
arm group type: Placebo Comparator
description: 12 weeks once daily placebo
intervention type: Drug
intervention name: PF-06700841
arm group label: PF-06700841 30mg once daily
arm group label: PF-06700841 30mg once daily followed by 100mg once weekly
arm group label: PF-06700841 30mg once daily followed by 10mg once daily
arm group label: PF-06700841 60 mg followed by 10 mg once daily
arm group label: PF-06700841 60 mg followed by 30 mg once daily
arm group label: PF-06700841 60mg once daily followed by 100mg once weekly
arm group label: PF-06700841 60mg once daily followed by placebo once daily
intervention type: Other
intervention name: Placebo
arm group label: Placebo
criteria: 
gender: All
minimum age: 18 Years
maximum age: 75 Years
healthy volunteers: No
last name: Pfizer CT.gov Call Center
role: Study Director
affiliation: Pfizer
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: Canada
country: Poland
country: United States
url: https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7931004&StudyName=A+Phase+2a%2C+Randomized%2C+Double-blind%2C+Placebo-controlled+Study+To+Evaluate+Safety+And+Efficacy+Of+Pf-06700841+In+Subjects+With+Moderate+To+Severe+Plaque+Psoriasis
description: To obtain contact information for a study center near you, click here.
responsible party type: Sponsor
mesh term: Psoriasis
mesh term: PF-06700841
sharing ipd: Yes
ipd description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
ipd url: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests
provided document: 
provided document: 
participant flow: 
baseline: 
outcome list: 
reported events: 
certain agreements: 
point of contact: 